{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:53:50Z","timestamp":1790258030734,"version":"4.1.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["101002571"],"award-info":[{"award-number":["101002571"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jconrel.2021.11.023","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:28:48Z","timestamp":1637425728000},"page":"170-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Pulmonary surfactant as a versatile biomaterial to fight COVID-19"],"prefix":"10.1016","volume":"342","author":[{"given":"Lore","family":"Herman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan C.","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Raemdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.11.023_bb0005","series-title":"WHO COVID-19 Dashboard [Internet]","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/17476348.2021.1865809","article-title":"The COVID-19 pandemic: a target for surfactant therapy?","volume":"15","author":"Veldhuizen","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1473-3099(20)30156-0","article-title":"COVID-19 with spontaneous pneumomediastinum","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/JMDH.S264168","article-title":"Optimizing supportive care in COVID-19 patients: A multidisciplinary approach","volume":"13","author":"Haleeqa","year":"2020","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fmed.2020.00254","article-title":"Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia","volume":"7","author":"Mirastschijski","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0030","article-title":"Analyzing the global impact of COVID-19 vaccination Progress: A result-oriented storytelling approach","author":"Kumar Dey","year":"2021","journal-title":"MedRxiv."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jconrel.2020.11.042","article-title":"Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant\/tacrolimus formulations","volume":"329","author":"Hidalgo","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0045","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0050","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3390\/jcm9040982","article-title":"Master regulator analysis of the SARS-CoV-2\/human interactome","volume":"9","author":"Guzzi","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/idr13020029","article-title":"COVID-19 treatment guidelines: do they really reflect best medical practices to manage the pandemic?","volume":"13","author":"Jirjees","year":"2021","journal-title":"Infect. Dis. Rep."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0060","author":"Kupferschmidt"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0065","unstructured":"Gilead. U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury\u00ae (remdesivir) for Treatment of COVID-19 [internet]. 2021. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/10\/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0075","first-page":"777","article-title":"Combination therapies for COVID-19: an overview of the clinical trials landscape","volume":"47","author":"Akinbolade","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0085","doi-asserted-by":"crossref","first-page":"635371","DOI":"10.3389\/fimmu.2021.635371","article-title":"Lack of effectiveness of repurposed drugs for COVID-19 treatment","volume":"12","author":"Martinez","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0095","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1111\/1462-2920.15769","article-title":"Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes","volume":"23","author":"Br\u00fcssow","year":"2021","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0100","series-title":"Atea Pharmaceuticals announces first patient dosed in global phase 3 MORNINGSKY trial of AT-527 for treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/d41586-021-03074-5","article-title":"COVID antiviral pills: what scientists still want to know","volume":"599","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0110","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2020.106408","article-title":"The chemistry, biology and pharmacology of the cyclopentenone prostaglandins","volume":"148","author":"Burstein","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0130","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1172\/JCI60331","article-title":"The acute respiratory distress syndrome","volume":"122","author":"Matthay","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0135","series-title":"Critical Care Medicine","first-page":"773","article-title":"Acute respiratory failure","author":"Gurka","year":"2008"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/jp.2009.31","article-title":"Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials","volume":"29","author":"Ramanathan","year":"2009","journal-title":"J. Perinatol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chest.2021.01.028","article-title":"Surfactant for the treatment of ARDS in a patient with COVID-19","volume":"160","author":"Heching","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0150","doi-asserted-by":"crossref","first-page":"103645","DOI":"10.1016\/j.resp.2021.103645","article-title":"Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): role in SARS-CoV-2-related lung injury","volume":"288","author":"Cattel","year":"2021","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0155","series-title":"A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 (COVSurf) [Internet]","year":"2020"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0160","author":"Lawson Health Research Institute"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0165","series-title":"Curosurf\u00ae in Adult Acute Respiratory Distress Syndrome Due to COVID-19 (Caards-1) [Internet]","year":"2020"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0170","series-title":"The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults with Coronavirus Disease 2019 (COVID-19) [Internet]","year":"2020"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0175","series-title":"Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid- 19) [Internet]","year":"2020"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0180","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpb.2015.02.014","article-title":"Barrier or carrier? Pulmonary surfactant and drug delivery","volume":"95","author":"Hidalgo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0190","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3389\/fbioe.2020.613276","article-title":"Pulmonary surfactant and drug delivery: an interface-assisted carrier to deliver surfactant protein SP-D into the airways","volume":"8","author":"Garc\u00eda-Mouton","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0195","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0022-2275(20)41642-6","article-title":"Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids","volume":"32","author":"Schmitz","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0200","first-page":"259","article-title":"Regulation of surfactant secretion in alveolar type II cells","volume":"293","author":"Andreeva","year":"2007","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0205","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fbioe.2020.00916","article-title":"Prospects for RNAi therapy of COVID-19","volume":"8","author":"Uluda\u011f","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0210","doi-asserted-by":"crossref","first-page":"2001650","DOI":"10.1002\/adhm.202001650","article-title":"siRNA therapeutics against respiratory viral infections\u2014what have we learned for potential COVID-19 therapies?","volume":"10","author":"Mehta","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0215","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ardp.201500120","article-title":"Pulmonary delivery of siRNA via polymeric vectors as therapies of asthma","volume":"348","author":"Xie","year":"2015","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0220","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0225","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/nnm.12.203","article-title":"The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels","volume":"8","author":"De Backer","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2015.03.015","article-title":"Bio-inspired pulmonary surfactant-modified nanogels: A promising siRNA delivery system","volume":"206","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2015.08.030","article-title":"Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages","volume":"217","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2020.09.011","article-title":"Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy","volume":"157","author":"Merckx","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0245","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.actbio.2018.08.012","article-title":"Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy","volume":"78","author":"Merckx","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0250","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1021\/acsnano.0c04489","article-title":"Surfactant protein B promotes cytosolic siRNA delivery by adopting a virus-like mechanism of action","volume":"15","author":"Guagliardo","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0255","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0260","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0265","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/ijbs.45053","article-title":"SARS-CoV-2: an emerging coronavirus that causes a global threat","volume":"16","author":"Zheng","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0270","doi-asserted-by":"crossref","first-page":"107233","DOI":"10.1016\/j.intimp.2020.107233","article-title":"Neutrophils and COVID-19: the road so far","volume":"90","author":"Cavalcante-Silva","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0275","series-title":"Fenner and White\u2019s Medical Virology","first-page":"437","article-title":"Coronaviruses","author":"Burrell","year":"2017"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0280","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0285","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1128\/JVI.01394-09","article-title":"Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission","volume":"84","author":"Graham","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13054-020-03399-z","article-title":"SARS-CoV-2 pneumonia-receptor binding and lung immunopathology: a narrative review","volume":"25","author":"Menezes","year":"2021","journal-title":"Crit. Care"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0295","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41581-020-00356-5","article-title":"COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) workgroup","volume":"16","author":"Nadim","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0305","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1093\/eurheartj\/ehaa872","article-title":"Implications of renal ACE2 expression in the age of COVID-19","volume":"41","author":"Salah","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0310","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0315","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0320","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0325","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fphys.2020.00227","article-title":"A physiologically informed strategy to effectively open, stabilize, and protect the acutely injured lung","volume":"11","author":"Nieman","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0330","doi-asserted-by":"crossref","first-page":"582895","DOI":"10.3389\/fimmu.2020.582895","article-title":"The inhibitory effect of Curosurf\u00ae and Alveofact\u00ae on the formation of neutrophil extracellular traps","volume":"11","author":"Schulz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.04.035","article-title":"Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant","volume":"568","author":"Blanco","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0340","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chemphyslip.2014.09.002","article-title":"Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films","volume":"185","author":"Parra","year":"2015","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0345","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-pathol-012513-104644","article-title":"Diseases of pulmonary surfactant homeostasis","volume":"10","author":"Whitsett","year":"2015","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0350","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.bbamem.2008.05.003","article-title":"Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions","volume":"1778","author":"P\u00e9rez-Gil","year":"2008","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0355","first-page":"259","article-title":"Clearance and recycling of pulmonary surfactant","volume":"259","author":"Wright","year":"1990","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1152\/ajplung.00341.2007","article-title":"Surfactant protein-A plays an important role in lung surfactant clearance: evidence using the surfactant protein-A gene-targeted mouse","volume":"294","author":"Bates","year":"2008","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000272062","article-title":"P63 (CKAP4) as an SP-A receptor: implications for surfactant turnover","volume":"25","author":"Bates","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0370","doi-asserted-by":"crossref","first-page":"532071","DOI":"10.1155\/2012\/532071","article-title":"Diverse functions of pulmonary collectins in host defense of the lung","volume":"2012","author":"Ariki","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0375","doi-asserted-by":"crossref","first-page":"22442","DOI":"10.1074\/jbc.M001107200","article-title":"Surfactant proteins A and D bind CD14 by different mechanisms","volume":"275","author":"Sano","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0380","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.1402289","article-title":"OSCAR is a receptor for surfactant protein D that activates TNF-\u03b1 release from human CCR2 + inflammatory monocytes","volume":"194","author":"Barrow","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0385","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1189\/jlb.3AB0213-092RR","article-title":"Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D","volume":"96","author":"Olde Nordkamp","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0390","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4049\/jimmunol.1501032","article-title":"Surfactant protein A prevents IFN-\u03b3\/IFN-\u03b3 receptor interaction and attenuates classical activation of human alveolar macrophages","volume":"197","author":"Minutti","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0395","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s42003-019-0662-5","article-title":"SP-D attenuates LPS-induced formation of human neutrophil extracellular traps (NETs), protecting pulmonary surfactant inactivation by NETs","volume":"2","author":"Arroyo","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0400","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12931-014-0085-2","article-title":"Surfactant protein A mediates pulmonary clearance of Staphylococcus aureus","volume":"15","author":"Veith","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0405","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/eji.1830270413","article-title":"Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages","volume":"27","author":"Benne","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0410","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1074\/jbc.M808643200","article-title":"Surfactant protein A modulates cell surface expression of CR3 on alveolar macrophages and enhances CR3-mediated phagocytosis","volume":"284","author":"Gil","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0415","doi-asserted-by":"crossref","first-page":"28438","DOI":"10.1074\/jbc.273.43.28438","article-title":"Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo","volume":"273","author":"Korfhagen","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0420","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2018.10.012","article-title":"Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins","volume":"291","author":"Guagliardo","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0425","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.bbamem.2014.01.028","article-title":"Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy","volume":"1838","author":"Lopez-Rodriguez","year":"2014","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0430","first-page":"132","article-title":"Pulmonary surfactant pathophysiology: current models and open questions","volume":"25","author":"P\u00e9rez-Gil","year":"2010","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0435","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00249-012-0858-9","article-title":"Structure-function correlations of pulmonary surfactant protein SP-B and the saposin-like family of proteins","volume":"42","author":"Olmeda","year":"2013","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0440","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1074\/jbc.275.5.3365","article-title":"The role of homodimers in surfactant protein B function in vivo","volume":"275","author":"Beck","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0445","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0006-3495(03)75002-4","article-title":"Effects of oligomerization and secondary structure on the surface behavior of pulmonary surfactant proteins SP-B and SP-C","volume":"84","author":"W\u00fcstneck","year":"2003","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0450","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1073\/pnas.92.17.7794","article-title":"Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice","volume":"92","author":"Clark","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0455","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM199302113280606","article-title":"Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis","volume":"328","author":"Nogee","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0460","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1021\/bi00185a042","article-title":"The NMR structure of the pulmonary surfactant-associated polypeptide SP-C in an apolar solvent contains a valyl-rich \u03b1-helix","volume":"33","author":"Johansson","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0465","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1073\/pnas.101500298","article-title":"Altered stability of pulmonary surfactant in SP-C-deficient mice","volume":"98","author":"Glasser","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0470","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1164\/rccm.200112-123OC","article-title":"Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred","volume":"165","author":"Thomas","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbamem.2014.10.009","article-title":"Palmitoylation as a key factor to modulate SP-C-lipid interactions in lung surfactant membrane multilayers","volume":"1848","author":"Roldan","year":"2015","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0480","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbamem.2009.05.011","article-title":"Cholesterol modulates the exposure and orientation of pulmonary surfactant protein SP-C in model surfactant membranes","volume":"1788","author":"G\u00f3mez-Gil","year":"2009","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0485","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.micinf.2006.04.009","article-title":"Surfactant protein C: its unique properties and emerging immunomodulatory role in the lung","volume":"8","author":"Mulugeta","year":"2006","journal-title":"Microbes Infect."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0490","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1152\/ajplung.00214.2005","article-title":"Reversibility of lung inflammation caused by SP-B deficiency","volume":"289","author":"Ikegami","year":"2005","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0495","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1073\/pnas.0909361107","article-title":"Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection","volume":"107","author":"Numata","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0500","doi-asserted-by":"crossref","first-page":"25488","DOI":"10.1074\/jbc.M109.040832","article-title":"Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2","volume":"284","author":"Kuronuma","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0505","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4049\/jimmunol.0900650","article-title":"Surfactant protein B propeptide contains a saposin-like protein domain with antimicrobial activity at low pH","volume":"184","author":"Yang","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0510","doi-asserted-by":"crossref","first-page":"23484","DOI":"10.1074\/jbc.M111925200","article-title":"Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide","volume":"277","author":"Augusto","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0515","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/1753425908100500","article-title":"Synthetic peptides representing the N-terminal segment of surfactant protein C modulate LPS-stimulated TNF-\u03b1 production by macrophages","volume":"15","author":"Garcia-Verdugo","year":"2009","journal-title":"Innate Immun."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/joim.12845","article-title":"Synthetic surfactants with SP-B and SP-C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases","volume":"285","author":"Johansson","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0525","doi-asserted-by":"crossref","first-page":"166749","DOI":"10.1016\/j.jmb.2020.166749","article-title":"Towards the molecular mechanism of pulmonary surfactant protein SP-B: at the crossroad of membrane permeability and interfacial lipid transfer","volume":"433","author":"Mart\u00ednez-Calle","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0530","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3389\/fimmu.2020.622598","article-title":"SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties","volume":"11","author":"Watson","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0535","first-page":"517","article-title":"Surface properties in relation to atelectasis and hyaline membrane disease","volume":"97","author":"Avery","year":"1959","journal-title":"AMA. J. Dis. Child."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0540","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199142050-00009","article-title":"Colfosceril palmitate: a review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (exosurf neonatal) in neonatal respiratory distress syndrome","volume":"42","author":"Dechant","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0545","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clp.2006.12.005","article-title":"Animal-derived surfactants versus past and current synthetic surfactants: current status","volume":"34","author":"Moya","year":"2007","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0675","first-page":"251","article-title":"Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials","volume":"5","author":"Logan","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0680","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3345\/kjp.2018.07185","article-title":"Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future","volume":"62","author":"Jeon","year":"2019","journal-title":"Korean J. Pediatr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0685","first-page":"499","article-title":"Waring, Advances in synthetic lung surfactant protein technology","volume":"13","author":"Walther","year":"2019","journal-title":"Exp. Rev. Resp. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0690","first-page":"e14700","article-title":"Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome","volume":"9","author":"Mikolka","year":"2021","journal-title":"Phys. Rep."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0550","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000084878","article-title":"History of surfactant up to 1980","volume":"87","author":"Obladen","year":"2005","journal-title":"Biol. Neonate"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0555","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.1955.02950300021004","article-title":"Controlled clinical trial of effects of alevaire mist on premature infants","volume":"157","author":"Silverman","year":"1955","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0560","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-291X(86)90026-4","article-title":"Proteolipid in bovine lung surfactant: its role in surfactant function","volume":"135","author":"Takahashi","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(80)90489-4","article-title":"Artificial surfactant therapy in hyaline-membrane disease","volume":"315","author":"Fujiwara","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0570","first-page":"CD000144","article-title":"Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome","volume":"2","author":"Soll","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0575","first-page":"CD000144","article-title":"Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome","volume":"8","author":"Ardell","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0580","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000381117","article-title":"A unique story in neonatal research: the development of a porcine surfactant","volume":"107","author":"Curstedt","year":"2015","journal-title":"Neonatology"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0585","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/jp.2008.50","article-title":"Surfactants: past, present and future","volume":"28","author":"Halliday","year":"2008","journal-title":"J. Perinatol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0590","first-page":"CD010249","article-title":"Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants","volume":"12","author":"Singh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0595","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/jp.2009.31","article-title":"Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials","volume":"292","author":"Ramanathan","year":"2009","journal-title":"J. Perinatol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0600","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cbpa.2016.02.012","article-title":"Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders","volume":"32","author":"Braide-Moncoeur","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0605","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2015.08.005","article-title":"Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials","volume":"34","author":"Zhang","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000451076","article-title":"Design of surfactant protein B peptide mimics based on the saposin fold for synthetic lung surfactants","volume":"1","author":"Walther","year":"2016","journal-title":"Biomed. Hub."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0615","doi-asserted-by":"crossref","first-page":"72821","DOI":"10.1371\/journal.pone.0072821","article-title":"Role of the N-terminal seven residues of surfactant protein B (SP-B)","volume":"8","author":"Sharifahmadian","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0620","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1371\/journal.pone.0008672","article-title":"Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs","volume":"5","author":"Walther","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0625","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7717\/peerj.1528","article-title":"Activity and biophysical inhibition resistance of a novel synthetic lung surfactant containing super-mini-B DATK peptide","volume":"4","author":"Notter","year":"2016","journal-title":"PeerJ."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0630","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000442874","article-title":"Phospholipid composition in synthetic surfactants is important for tidal volumes and alveolar stability in surfactant-treated preterm newborn rabbits","volume":"109","author":"Calkovska","year":"2016","journal-title":"Neonatology"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0635","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/bj3070535","article-title":"Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SP-C","volume":"307","author":"Johansson","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0640","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1432-1327.1998.2550116.x","article-title":"Synthetic peptide-containing surfactants. Evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution","volume":"255","author":"Nilsson","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0645","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1432-1033.1995.tb20487.x","article-title":"Structural and functional importance of the C-terminal part of the pulmonary surfactant polypeptide SP-C","volume":"229","author":"Clercx","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0650","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1152\/japplphysiol.00153.2003","article-title":"A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits","volume":"95","author":"Johansson","year":"2003","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0655","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbamem.2011.01.013","article-title":"Alterations of the C-terminal end do not affect in vitro or in vivo activity of surfactant protein C analogs","volume":"1818","author":"Alml\u00e9n","year":"2012","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0660","doi-asserted-by":"crossref","first-page":"e47631","DOI":"10.1371\/journal.pone.0047631","article-title":"New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs","volume":"7","author":"Seehase","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0665","doi-asserted-by":"crossref","first-page":"e39392","DOI":"10.1371\/journal.pone.0039392","article-title":"SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung","volume":"7","author":"Sato","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0670","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17476348.2019.1589372","article-title":"Advances in synthetic lung surfactant protein technology","volume":"13","author":"Walther","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0695","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/ers.10.92","article-title":"Pathogenesis of indirect (secondary) acute lung injury","volume":"5","author":"Perl","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0700","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1529\/biophysj.105.062620","article-title":"Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental","volume":"89","author":"Taeusch","year":"2005","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0715","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0720","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1021\/acs.biomac.7b00572","article-title":"Anti-inflammatory effect of anti-TNF-\u03b1 siRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model","volume":"18","author":"Bohr","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0725","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2013.12.008","article-title":"Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury","volume":"175","author":"Oh","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0730","first-page":"1640","article-title":"The role of pulmonary surfactants in the treatment of acute respiratory distress syndrome in COVID-19","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0735","doi-asserted-by":"crossref","first-page":"e20200652","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0740","first-page":"259","article-title":"Vaccine against arteriosclerosis: an update","volume":"9","author":"Soiza","year":"2018","journal-title":"Ther. Adv. Vacc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0745","first-page":"4639","article-title":"Immunohistochemical findings in the lungs of COVID-19 subjects: evidence of surfactant dysregulation","volume":"25","author":"Gerosa","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76404-8","article-title":"Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy","volume":"10","author":"Islam","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0755","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00408-020-00393-8","article-title":"Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19?","volume":"198","author":"Kerget","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0760","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12879-021-06447-3","article-title":"Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity","volume":"21","author":"Tong","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0765","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.M065201","article-title":"Structural analogs of pulmonary surfactant phosphatidylglycerol inhibit toll-like receptor 2 and 4 signaling","volume":"57","author":"Kandasamy","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0775","first-page":"1417","article-title":"Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung","volume":"8","author":"Numata","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0780","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1194\/jlr.M055723","article-title":"Phosphatidylinositol inhibits respiratory syncytial virus infection","volume":"56","author":"Numata","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0790","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1165\/rcmb.2011-0194OC","article-title":"Phosphatidylglycerol suppresses influenza A virus infection","volume":"46","author":"Numata","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0795","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0800","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0805","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1099\/vir.0.038414-0","article-title":"Infection of human alveolar macrophages by human coronavirus strain 229E","volume":"93","author":"Joel Funk","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0810","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.imbio.2006.12.001","article-title":"The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages","volume":"212","author":"Leth-Larsen","year":"2007","journal-title":"Immunobiology"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0815","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1152\/ajplung.1991.261.2.L204","article-title":"Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages","volume":"261","author":"van Iwaarden","year":"1991","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0820","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00705-016-2838-3","article-title":"Antiviral activity of recombinant porcine surfactant protein A against porcine reproductive and respiratory syndrome virus in vitro","volume":"161","author":"Li","year":"2016","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0825","doi-asserted-by":"crossref","first-page":"20140049","DOI":"10.1098\/rstb.2014.0049","article-title":"Nanoparticles modulate surfactant protein A and D mediated protection against influenza A infection in vitro","volume":"370","author":"McKenzie","year":"2014","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0830","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/v5030928","article-title":"Protective effect of surfactant protein D in pulmonary vaccinia virus infection: implication of A27 viral protein","volume":"5","author":"Perino","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0835","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2013.12.032","article-title":"Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo","volume":"181","author":"Hillaire","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0840","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1164\/rccm.201612-2415CI","article-title":"Insight into acute respiratory distress syndrome: from models to patients","volume":"196","author":"Laffey","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0845","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1039\/C5SM00926J","article-title":"Overcoming inactivation of the lung surfactant by serum proteins: A potential role for fluorocarbons?","volume":"11","author":"Krafft","year":"2015","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0850","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-3495(04)74165-X","article-title":"Electrostatic barrier to recovery of dipalmitoylphosphatidylglycerol monolayers after collapse","volume":"86","author":"Alig","year":"2004","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0855","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0925-4439(98)00067-2","article-title":"Formation and structure of surface films: captive bubble surfactometry","volume":"1408","author":"Sch\u00fcrch","year":"1998","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0860","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1165\/rcmb.2021-0005OC","article-title":"A recombinant fragment of human surfactant protein D binds spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples","volume":"65","author":"Madan","year":"2021","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0865","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2021.641360","article-title":"Human surfactant protein D binds S1 and receptor binding domain of spike protein and acts as an entry inhibitor of SARS-CoV-2 pseudotyped viral particles in vitro","volume":"12","author":"Hsieh","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0870","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1203\/00006450-200107000-00010","article-title":"Resistance of different surfactant preparations to inactivation by meconium","volume":"50","author":"Herting","year":"2001","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0875","doi-asserted-by":"crossref","first-page":"e0153578","DOI":"10.1371\/journal.pone.0153578","article-title":"Impact of the new generation reconstituted surfactant CHF5633 on human CD4+ lymphocytes","volume":"11","author":"Fehrholz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0880","doi-asserted-by":"crossref","first-page":"e0146898","DOI":"10.1371\/journal.pone.0146898","article-title":"Effects of the new generation synthetic reconstituted surfactant CHF5633 on proand anti-inflammatory cytokine expression in native and LPS-stimulated adult CD14+ monocytes","volume":"11","author":"Glaser","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0885","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14787210.2017.1259067","article-title":"Anti-inflammatory effects of the new generation synthetic surfactant CHF5633 on ureaplasma-induced cytokine responses in human monocytes","volume":"15","author":"Glaser","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0890","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1183\/09031936.02.00243402","article-title":"Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics","volume":"19","author":"Walmrath","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0895","first-page":"11","article-title":"Exogenous surfactant: intubated present, nebulized future?","volume":"7","author":"Shah","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0900","first-page":"8959370","article-title":"Inhalation techniques used in patients with respiratory failure treated with noninvasive mechanical ventilation","volume":"2018","author":"Rzepka-Wrona","year":"2018","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0905","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4187\/respcare.05803","article-title":"How should aerosols be delivered during invasive mechanical ventilation?","volume":"62","author":"Dhand","year":"2017","journal-title":"Respir. Care"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0910","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4187\/respcare.03579","article-title":"Aerosolized surfactants, anti-inflammatory drugs, and analgesics","volume":"60","author":"Willson","year":"2015","journal-title":"Respir. Care"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0915","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1203\/00006450-198309000-00012","article-title":"Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity","volume":"17","author":"Marks","year":"1983","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0920","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1034\/j.1399-6576.2000.00521.x","article-title":"Aerosolized surfactant in lung-lavaged adult rats: factors influencing the therapeutic response","volume":"44","author":"Bahlmann","year":"2000","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0925","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/ajrccm.161.1.9812017","article-title":"Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA\/Q) mismatch in a model of acute lung injury","volume":"161","author":"Schermuly","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466620951043","article-title":"Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia","volume":"14","author":"Busani","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-020-01603-w","article-title":"Surfactant therapy for COVID-19 related ARDS: a retrospective case\u2013control pilot study","volume":"22","author":"Piva","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0945","series-title":"Handbook of Non-invasive Drug Delivery Systems","first-page":"209","article-title":"Pulmonary drug delivery","author":"Ali","year":"2010"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0950","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/srep07085","article-title":"Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases","volume":"4","author":"Joshi","year":"2014","journal-title":"Sci.Rep."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0955","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0965","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0970","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","author":"The RECOVERY collaborative group","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0980","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0985","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb0990","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb0995","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.resinv.2019.12.005","article-title":"Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells","volume":"58","author":"Yamaya","year":"2020","journal-title":"Respir. Investig."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1000","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1465-9921-14-98","article-title":"Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses","volume":"14","author":"Bochkov","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1005","doi-asserted-by":"crossref","first-page":"e01648","DOI":"10.1128\/JVI.01648-20","article-title":"The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells","volume":"95","author":"Matsuyama","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1010","unstructured":"Covis Pharma. Covis Pharma Group announces top-line safety and efficacy data from a phase 3 placebo controlled COVID-19 study using inhaled corticosteroid (ciclesonide) [Internet]. 2021. Available from: https:\/\/covispharma.com\/index.php\/press-release-3\/."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","article-title":"Dexamethasone nanomedicines for COVID-19","volume":"15","author":"Lammers","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1020","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbamem.2017.04.019","article-title":"Pulmonary surfactant and nanocarriers: toxicity versus combined nanomedical applications","volume":"1859","author":"Hidalgo","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1025","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/TA.0b013e318265cbe9","article-title":"Therapeutic effects of inhaling aerosolized surfactant alone or with dexamethasone generated by a novel noninvasive apparatus on acute lung injury in rats","volume":"73","author":"Yan","year":"2012","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1030","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1021\/acs.langmuir.7b01177","article-title":"Efficient interfacially driven vehiculization of corticosteroids by pulmonary surfactant","volume":"33","author":"Hidalgo","year":"2017","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1476-5381.1996.tb16016.x","article-title":"Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae","volume":"119","author":"Van\u2019t Veen","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1040","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1021\/bi036227z","article-title":"Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity","volume":"43","author":"Canadas","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1045","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1128\/AAC.04937-14","article-title":"Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia","volume":"59","author":"Banaschewski","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1050","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1164\/ajrccm.159.6.9810047","article-title":"Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia","volume":"159","author":"Herting","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1055","first-page":"613","article-title":"Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits","volume":"269","author":"Walther","year":"1995","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/hum.1997.8.2-171","article-title":"Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung","volume":"8","author":"Katkin","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4081\/mrm.2020.511","article-title":"Ambroxol for the treatment of children with acute and chronic respiratory diseases: an overview of efficacy and safety","volume":"15","author":"Kantar","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1070","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1517\/17460441.2011.629646","article-title":"Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood","volume":"6","author":"Paleari","year":"2011","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1080","doi-asserted-by":"crossref","first-page":"577172","DOI":"10.3389\/fbioe.2020.577172","article-title":"Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS intervention: what are we waiting for?","volume":"8","author":"Kumar","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bcp.12987","article-title":"Therapeutic nucleic acids: current clinical status","volume":"82","author":"Sridharan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","article-title":"Molecular mechanisms of RNA interference","volume":"42","author":"Wilson","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2008.06.008","article-title":"Maintaining the silence: reflections on long-term RNAi","volume":"13","author":"Raemdonck","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrd1345","article-title":"siRNAs: applications in functional genomics and potential as therapeutics","volume":"3","author":"Dorsett","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000112792","article-title":"RNAi mechanisms and applications","volume":"44","author":"Kim","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-1-34","article-title":"Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses","volume":"1","author":"Bitko","year":"2001","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1130","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1135","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1140","doi-asserted-by":"crossref","first-page":"102097","DOI":"10.1016\/j.msard.2020.102097","article-title":"Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: a new challenge","volume":"41","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1155","first-page":"528","article-title":"siRNA could be a potential therapy for COVID-19","volume":"19","author":"Ghosh","year":"2020","journal-title":"EXCLI J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1160","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fbioe.2020.00916","article-title":"Prospects for RNAi therapy of COVID-19","volume":"8","author":"Uluda\u011f","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1165","first-page":"1","article-title":"Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility","author":"Ian Gallicano","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/d41586-021-00065-4","article-title":"Alarming COVID variants show vital role of genomic surveillance","volume":"589","author":"Cyranoski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1175","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.nano.2017.04.005","article-title":"Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s)","volume":"13","author":"Garbuzenko","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1180","doi-asserted-by":"crossref","first-page":"1903277","DOI":"10.1002\/adma.201903277","article-title":"ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy","volume":"31","author":"Zheng","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1185","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1021\/acs.molpharmaceut.6b00711","article-title":"Single and combinational siRNA therapy of cancer cells: probing changes in targeted and nontargeted mediators after siRNA treatment","volume":"13","author":"Aliabadi","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1190","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.actbio.2017.11.036","article-title":"Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells","volume":"66","author":"Parmar","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/bc200296q","article-title":"Pulmonary gene delivery using polymeric nonviral vectors","volume":"23","author":"Merkel","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.addr.2014.05.018","article-title":"siRNA delivery to the lung: what\u2019s new?","volume":"75","author":"Merkel","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1205","doi-asserted-by":"crossref","first-page":"11872","DOI":"10.1021\/acsnano.5b04215","article-title":"Proteomic and lipidomic analysis of nanoparticle corona upon contact with lung surfactant reveals differences in protein, but not lipid composition","volume":"9","author":"Raesch","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1210","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1021\/nn4054683","article-title":"Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona","volume":"7","author":"Hu","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1215","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/17435390.2016.1214762","article-title":"Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells","volume":"10","author":"Theodorou","year":"2017","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/jamp.2009.0797","article-title":"Update on macrophage clearance of inhaled micro- and nanoparticles","volume":"23","author":"Geiser","year":"2010","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1225","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/nn2015997","article-title":"Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant","volume":"5","author":"Fan","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1230","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bpj.2014.08.010","article-title":"Investigating the effect of particle size on pulmonary surfactant phase behavior","volume":"107","author":"Kodama","year":"2014","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1235","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1529\/biophysj.107.106971","article-title":"Metal nanoparticle pollutants interfere with pulmonary surfactant function in vitro","volume":"94","author":"Bakshi","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.nano.2011.07.009","article-title":"Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A","volume":"7","author":"Ruge","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1245","doi-asserted-by":"crossref","DOI":"10.1055\/s-0031-1296141","article-title":"Role of surfactant proteins in the interaction of nanoparticles with the air-blood-barrier","volume":"65","author":"Ruge","year":"2011","journal-title":"Pneumologie"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1250","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3109\/17435390.2016.1155671","article-title":"Influence of agglomeration and specific lung lining lipid\/protein interaction on short-term inhalation toxicity","volume":"10","author":"Wohlleben","year":"2016","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0001-8686(86)80012-4","article-title":"Adsorption of proteins from solution at the solid-liquid interface","volume":"25","author":"Norde","year":"1986","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.nano.2010.10.007","article-title":"Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro","volume":"7","author":"Beck-Broichsitter","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1265","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.bbamem.2013.10.016","article-title":"Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles","volume":"1838","author":"Beck-Broichsitter","year":"2014","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2014.03.034","article-title":"Endosome maturation, transport and functions","volume":"31","author":"Scott","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1275","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jconrel.2015.09.004","article-title":"Bio-inspired materials in drug delivery: exploring the role of pulmonary surfactant in siRNA inhalation therapy","volume":"220","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1280","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/adfm.200801795","article-title":"Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery","volume":"19","author":"Raemdonck","year":"2009","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1285","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11095-011-0589-0","article-title":"Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression","volume":"29","author":"Jensen","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1290","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bpj.2019.11.2210","article-title":"Functional and structural characterization of a lyophilized pulmonary surfactant directly applied onto the air-liquid interface","volume":"118","author":"Echaide","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/jamp.2018.1505","article-title":"Deposition of aerosolized lucinactant in nonhuman primates","volume":"33","author":"Gregory","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1300","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/pr.2012.46","article-title":"Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress","volume":"721","author":"Mazela","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1305","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1096\/fj.15-273458","article-title":"A model for the structure and mechanism of action of pulmonary surfactant protein B","volume":"29","author":"Olmeda","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2021.11.023_bib1321","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090431","article-title":"Nanocarrier lipid composition modulates the impact of pulmonary surfactant protein B (SP-B) on cellular delivery of siRNA","volume":"11","author":"Guagliardo","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.11.023_bb1310","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.chembiol.2016.03.016","article-title":"The late endosome and its lipid BMP act as gateways for efficient cytosolic access of the delivery agent dfTAT and its macromolecular cargos","volume":"23","author":"Erazo-Oliveras","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1315","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/acs.molpharmaceut.7b00725","article-title":"From pulmonary surfactant, synthetic KL4 peptide as effective siRNA delivery vector for pulmonary delivery","volume":"14","author":"Qiu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.11.023_bb1320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921006180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921006180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:11:12Z","timestamp":1759162272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921006180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":258,"alternative-id":["S0168365921006180"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.023","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary surfactant as a versatile biomaterial to fight COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}